000301504 001__ 301504
000301504 005__ 20250530125759.0
000301504 0247_ $$2doi$$a10.1016/j.celrep.2025.115673
000301504 0247_ $$2pmid$$apmid:40393452
000301504 0247_ $$2ISSN$$a2211-1247
000301504 0247_ $$2ISSN$$a2639-1856
000301504 0247_ $$2altmetric$$aaltmetric:177232377
000301504 037__ $$aDKFZ-2025-01043
000301504 041__ $$aEnglish
000301504 082__ $$a610
000301504 1001_ $$aWang, Wanchen$$b0
000301504 245__ $$aChromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression.
000301504 260__ $$aMaryland Heights, MO$$bCell Press$$c2025
000301504 3367_ $$2DRIVER$$aarticle
000301504 3367_ $$2DataCite$$aOutput Types/Journal article
000301504 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748602640_4071
000301504 3367_ $$2BibTeX$$aARTICLE
000301504 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301504 3367_ $$00$$2EndNote$$aJournal Article
000301504 500__ $$aVolume 44, Issue 5, 27 May 2025, 115673
000301504 520__ $$aMedulloblastoma (MB), a common malignant pediatric brain tumor arising in the cerebellum, is characterized by mutations in chromatin modifiers, highlighting the significance of chromatin modification abnormalities in its progression. While animal models have effectively demonstrated this, a comprehensive evaluation of the oncogenic potential of these mutations remains incomplete. In this study, we use CRISPR-mediated gene editing to knock out chromatin modifier genes mutated in human SHH MB, along with the Ptch1 gene, in cerebellar granule neuron progenitors of neonatal mice. This reveals that depletion of Chd7 and Kmt2c accelerates tumor growth. Multi-layered omics analysis uncovers that inhibition of the neuronal differentiation program by chromatin dysregulation is a key signaling pathway in tumor progression. Additionally, forced expression of Neurod1, a common target of these chromatin modifiers, inhibits proliferation and promotes differentiation. These findings highlight converging chromatin modification abnormalities from distinct mutations in Sonic Hedgehog MB and suggest that epigenetic drugs activating neuronal genes have significant potential as novel treatments.
000301504 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000301504 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301504 650_7 $$2Other$$aCHD7
000301504 650_7 $$2Other$$aCP: Cancer
000301504 650_7 $$2Other$$aKMT2C
000301504 650_7 $$2Other$$abrain tumor
000301504 650_7 $$2Other$$achromatin modifications
000301504 650_7 $$2Other$$amedulloblastoma
000301504 650_7 $$2Other$$amouse model
000301504 7001_ $$aKumegawa, Kohei$$b1
000301504 7001_ $$aChapman, Owen S$$b2
000301504 7001_ $$aShiraishi, Ryo$$b3
000301504 7001_ $$aXiao, Zhize$$b4
000301504 7001_ $$0P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aOkonechnikov, Konstantin$$b5$$udkfz
000301504 7001_ $$aSun, Yang$$b6
000301504 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b7$$udkfz
000301504 7001_ $$aFeng, Weijun$$b8
000301504 7001_ $$aUesaka, Naofumi$$b9
000301504 7001_ $$aHoshino, Mikio$$b10
000301504 7001_ $$aTakahashi, Satoru$$b11
000301504 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b12$$udkfz
000301504 7001_ $$aChavez, Lukas$$b13
000301504 7001_ $$aMaruyama, Reo$$b14
000301504 7001_ $$aKawauchi, Daisuke$$b15
000301504 773__ $$0PERI:(DE-600)2649101-1$$a10.1016/j.celrep.2025.115673$$gp. 115673 -$$n5$$p115673$$tCell reports$$v44$$x2211-1247$$y2025
000301504 909CO $$ooai:inrepo02.dkfz.de:301504$$pVDB
000301504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000301504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000301504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000301504 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000301504 9141_ $$y2025
000301504 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL REP : 2022$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:49:39Z
000301504 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:49:39Z
000301504 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T08:49:39Z
000301504 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELL REP : 2022$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-16
000301504 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-16
000301504 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000301504 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x1
000301504 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000301504 980__ $$ajournal
000301504 980__ $$aVDB
000301504 980__ $$aI:(DE-He78)B062-20160331
000301504 980__ $$aI:(DE-He78)B300-20160331
000301504 980__ $$aI:(DE-He78)HD01-20160331
000301504 980__ $$aUNRESTRICTED